Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 4 | 2023 | 542 | 1.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2023 | 1196 | 1.010 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 20 | 0.640 |
Why?
|
| Periosteum | 1 | 2019 | 33 | 0.620 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 319 | 0.520 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 427 | 0.470 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 532 | 0.410 |
Why?
|
| Transplantation Conditioning | 4 | 2023 | 323 | 0.260 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 28 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 33 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.210 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 123 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 145 | 0.200 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 78 | 0.180 |
Why?
|
| RNA, Viral | 1 | 2022 | 540 | 0.170 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 293 | 0.160 |
Why?
|
| Acute Disease | 1 | 2022 | 1090 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 334 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 178 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 804 | 0.130 |
Why?
|
| Child | 7 | 2023 | 24219 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 352 | 0.120 |
Why?
|
| Alemtuzumab | 2 | 2023 | 88 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2017 | 653 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2017 | 509 | 0.100 |
Why?
|
| Humans | 10 | 2023 | 123122 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2023 | 13874 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2023 | 16003 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 2762 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1115 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 141 | 0.050 |
Why?
|
| Texas | 2 | 2021 | 3546 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 49 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 659 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 296 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2021 | 82 | 0.050 |
Why?
|
| Rituximab | 1 | 2022 | 155 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 420 | 0.050 |
Why?
|
| Recurrence | 1 | 2023 | 1422 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 397 | 0.040 |
Why?
|
| Infant | 2 | 2023 | 12334 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1231 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 19091 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 19072 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1104 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1240 | 0.030 |
Why?
|
| Female | 1 | 2019 | 65443 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6028 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1993 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 8864 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3334 | 0.020 |
Why?
|
| Middle Aged | 1 | 2022 | 25971 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 29030 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 12121 | 0.010 |
Why?
|
| Male | 1 | 2021 | 60036 | 0.010 |
Why?
|